Kong Fangfang, Ying Hongmei, Zhai Ruiping, Du Chengrun, Huang Shuang, Zhou Junjun, He Xiayun, Hu Chaosu, Wang Zhuoying, Sun Tuanqi, Ji Qinghai
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Oncotarget. 2016 Dec 6;7(49):81899-81905. doi: 10.18632/oncotarget.11914.
To evaluate the efficacy and toxicity of adjuvant intensity-modulated radiotherapy (IMRT) after surgery for carcinoma showing thymus-like differentiation (CASTLE).
Between September 2008 and June 2015, 14 CASTLE patients were retrospectively enrolled. The clinical features, treatment procedure and clinical outcomes were reviewed. All patients received postoperative IMRT. The radiation doses ranged from 56Gy/28 fractions to 66Gy/33 fractions. Treatment-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.
After a median follow-up period of 42 months, only one patient suffered local recurrence and distant metastasis. The most frequently seen acute toxicities were mucositis and dermatitis (grade 1-2). No grade 3-4 toxicities were observed.
Although based upon a small series of consecutively treated patients, our study showed that adjuvant IMRT provides satisfactory local-regional control for CASTLE, with acceptable toxicities. Further studies are still warranted to clarify our findings.
评估辅助调强放疗（IMRT）对胸腺样分化癌（CASTLE）术后的疗效及毒性。
回顾性纳入2008年9月至2015年6月期间的14例CASTLE患者。对其临床特征、治疗过程及临床结局进行分析。所有患者均接受术后IMRT。放疗剂量范围为56Gy/28次分割至66Gy/33次分割。治疗相关毒性按照美国国立癌症研究所通用毒性标准（NCI-CTC）3.0版进行分级。
中位随访42个月后，仅1例患者出现局部复发和远处转移。最常见的急性毒性反应为黏膜炎和皮炎（1-2级）。未观察到3-4级毒性反应。
尽管本研究基于一小系列连续治疗的患者，但结果显示辅助IMRT可为CASTLE提供满意的局部区域控制，且毒性可接受。仍需进一步研究以明确本研究结果。
